Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | RRM1 | P23921 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL9989696 | 1.00 | GSR (0.59) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL23364070 | 0.98 | GSR (0.58) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL23364069 | 0.98 | GSR (0.58) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL1227757 | 0.98 | GSR (0.61) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL25278795 | 0.98 | GSR (0.61) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL8957537 | 0.97 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL4954180 | 0.97 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL3516723 | 0.97 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL15022773 | 0.97 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL11660904 | 0.97 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021097228-A1 | COMPOSITIONS AND SALTS FOR IMPROVING L-ARGININE BIOAVAILABILITY | THE GENERAL HOSPITAL CORPORATION (US) | 2021-05-20 | — | — | WO | claimed |
| US-20170327830-A1 | ATTENUATED LIVE BACTERIA WITH INCREASED ACID RESISTANCE AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH | 2017-11-16 | — | — | US | claimed |
| US-9580718-B2 | Attenuated live bacteria with increased acid resistance and methods of use thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-28 | — | — | US | claimed |
| US-20140370057-A1 | ATTENUATED LIVE BACTERIA WITH INCREASED ACID RESISTANCE AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-18 | — | — | US | claimed |
| US-20240191267-A1 | Tropane Alkaloid Transporters and Methods of Making Tropane Alkaloids Using the Same | HERCULES CAPITAL, INC., AS AGENT | 2024-06-13 | — | — | US | disclosed |
| EP-4314301-A1 | TROPANE ALKALOID TRANSPORTERS AND METHODS OF MAKING TROPANE ALKALOIDS USING THE SAME | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220170026-A1 | TROPANE ALKALOID (TA) PRODUCING NON-PLANT HOST CELLS, AND METHODS OF MAKING AND USING THE SAME | HERCULES CAPITAL, INC., AS AGENT | 2022-06-02 | — | — | US | disclosed |
| US-11254713-B2 | Method to enhance immunogenicity of live typhoid vaccines and carriers | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3934765-A1 | TROPANE ALKALOID (TA) PRODUCING NON-PLANT HOST CELLS, AND METHODS OF MAKING AND USING THE SAME | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-113784758-A | Non-plant host cells that produce Tropane Alkaloids (TA) and methods of making and using the same | 小利兰·斯坦福大学托管委员会 | 2021-12-10 | — | — | CN | disclosed |
| US-11166979-B1 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2021097228-A1 | COMPOSITIONS AND SALTS FOR IMPROVING L-ARGININE BIOAVAILABILITY | THE GENERAL HOSPITAL CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
| US-8957101-B1 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2015-02-17 | — | — | US | disclosed |
| US-8952046-B1 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952045-B1 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140370057-A1 | ATTENUATED LIVE BACTERIA WITH INCREASED ACID RESISTANCE AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-18 | — | — | US | disclosed |
| US-8466187-B2 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-8455531-B2 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2013-06-04 | — | — | US | disclosed |
| US-8344014-B2 | — | — | 2013-01-01 | — | — | US | disclosed |
| US-20110313043-A1 | Amino Acid Compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313043-A1 | Amino Acid Compositions | ARGLU1, AADAT, MUSK | GSR 412/4885OTC 42/4885GNAI3 2943/4885 |
| US-11166979-B1 | Amino acid compositions | SLC10A2, SLC1A5, CPT1B | GSR 1123/4885OTC 81/4885GNAI3 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.